We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SFX-01

News List

Evgen Pharma recruits over 100 patients into COVID-19 trial pharmatimes
February 19, 2021
UK-based Evgen Pharma has announced that it has now recruited a total of 102 patients into a trial investigating its lead asset SFX-01 in COVID-19.
Evgen scores full approval for COVID-19 trial launch pharmatimes
October 28, 2020
Evgen Pharma has received full regulatory approval for its STAR trial, which will investigate the company’s lead asset to treat acute respiratory distress syndrome (ARDS) in patients with suspected COVID-19.
Evgen's SFX-01 selected for COVID-19 trial pharmatimes
June 18, 2020
Evgen Pharma's lead candidate SFX-01 has been selected for evaluation in a randomised Phase II/III trial, to be sponsored by the University of Dundee, which aims to investigate its potential as a treatment for COVID-19.